Sequential Immunochemotherapy Treatment with Pembrolizumab Plus Dendritic Cell (DC) Vaccine Followed by Trifluridine/Tipiracil Plus Bevacizumab in Refractory Mismatch-repair-proficient (pMMR) or Microsatellite-stable (MSS) Metastatic Colorectal Cancer

Clinical trial NCT06522919 · RECRUITING

Trial details

NCT number: NCT06522919
Sponsor: Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Colorectal Cancer Metastatic Microsatellite Stable Colorectal Carcinoma Refractory Mismatch-repair-proficient (pMMR) Metastatic Colorectal Cancer

Start date: 2025-01-07
Primary completion: 2026-04-01
Enrollment: 36

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.